Fiducial-based image-guided SBRT for pancreatic adenocarcinoma: Does inter-and intra-fraction treatment variation warrant adaptive therapy?

by Colin S. Hill, Sarah Han-Oh, Zhi Cheng, Ken Kang-Hsin Wang, Jeffrey J. Meyer, Joseph M. Herman, Amol K. Narang
Published 2021-03-01

Resectable pancreatic small cell carcinoma

by Dana K. Andersen, Robert C. Miller, Ralph H. Hruban, Matthew T. Olson, Fred E. Eckhauser, Dan Laheru, John L. Cameron, Joseph M. Herman, Amol K. Narang, Aaron S. Mansfield, Jordan M. Winter
Published 2011-03-01

Long-term analysis of 2 prospective studies that incorporate mitomycin C into an adjuvant chemoradiation regimen for pancreatic and periampullary cancers

by Kathryn J. Schunke, PhD, Lauren M. Rosati, BS, Marianna Zahurak, MS, Joseph M. Herman, MD, MSc, Amol K. Narang, MD, Irina Usach, Alison P. Klein, MHS, PhD, Charles J. Yeo, MD, Larry T. Korman, BSN, Ralph H. Hruban, MD, John L. Cameron, MD, Daniel A. Laheru, MD, Ross A. Abrams, MD
Published 2018-01-01

Improving prediction of surgical resectability over current staging guidelines in patients with pancreatic cancer who receive stereotactic body radiation therapy

by Zhi Cheng, MD, MPH, Lauren M. Rosati, BS, Linda Chen, MD, Omar Y. Mian, MD, PhD, Yilin Cao, MD, Marta Villafania, BS, Minoru Nakatsugawa, PhD, Joseph A. Moore, PhD, Scott P. Robertson, PhD, Juan Jackson, BS, Amy Hacker-Prietz, PA-C, Jin He, MD, PhD, Christopher L. Wolfgang, MD, PhD, Matthew J. Weiss, MD, Joseph M. Herman, MD, MS, Amol K. Narang, MD, Todd R. McNutt, PhD
Published 2018-10-01